From d5815ebe69d59073b4148625032ba042f8a52a44 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 11:46:19 +0000 Subject: [PATCH] extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...oss-with-inflammation-as-primary-mediator.md | 12 ++++++++++++ ...t-adiposity-independent-cv-outcomes-2025.txt | 3 +++ ...ct-adiposity-independent-cv-outcomes-2025.md | 17 ++++++++++++++++- 3 files changed, 31 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.prior-art/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.txt diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md index 12a92333c..a95e3743d 100644 --- a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md +++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md @@ -60,6 +60,18 @@ ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via d ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss. +### Additional Evidence (confirm) +*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30* + +SELECT trial prespecified analysis (N=17,604, published Lancet November 2025) confirms semaglutide reduced MACE consistently across ALL baseline BMI and waist circumference categories with no evidence of treatment heterogeneity by adiposity level. Approximately 67% of MACE benefit is independent of adiposity/weight change. This is stronger evidence than the ESC 2024 abstract because it's a prespecified, not exploratory, analysis. The flat treatment effect across weight-change categories directly contradicts the hypothesis that benefit concentrates in patients achieving significant weight loss. + +### Additional Evidence (extend) +*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30* + +Complementary ESC 2024 mediation analysis (Colhoun/Lincoff) quantifies specific mediators: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation) mediates 42.1% — making anti-inflammatory pathways the largest single measured mediator, more than double the contribution of weight loss. Joint mediation of all measured factors accounts for only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% pleiotropic/unexplained. The convergence of two independent analyses (67% and 68.6% weight-independent) strengthens the claim that GLP-1s function primarily as anti-inflammatory cardiovascular drugs. + + + Relevant Notes: - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] diff --git a/inbox/queue/.prior-art/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.txt b/inbox/queue/.prior-art/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.txt new file mode 100644 index 000000000..002140a04 --- /dev/null +++ b/inbox/queue/.prior-art/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.txt @@ -0,0 +1,3 @@ +## Prior Art (automated pre-screening) + +- [semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator](domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md) — similarity: 0.74 — matched query: "semaglutide cardiovascular benefit independent of weight loss mechanisms" diff --git a/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md b/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md index f29be32cc..6ad92b414 100644 --- a/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md +++ b/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md @@ -7,9 +7,14 @@ date: 2025-11-01 domain: health secondary_domains: [] format: journal-article -status: unprocessed +status: enrichment priority: high tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mechanism, adiposity, MACE] +processed_by: vida +processed_date: 2026-03-30 +enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"] +extraction_model: "anthropic/claude-sonnet-4.5" +extraction_notes: "pre-screen: 1 prior art claims from 5 themes" --- ## Content @@ -56,3 +61,13 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mec PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Closes active thread on GLP-1 CV mechanism; establishes weight-independence as the primary clinical finding; connects GLP-1 benefit to SDOH-generated inflammatory pathways EXTRACTION HINT: Focus on the 67-69% weight-independence figure and the hsCRP mediation (42.1%) — together these establish the anti-inflammatory mechanism. Extract as mechanism claim, not just efficacy claim. Consider whether this should be a divergence with the existing GLP-1 claim that frames the drug primarily through metabolic/weight-loss lens. + + +## Key Facts +- SELECT trial enrolled 17,604 adults ≥45 with BMI ≥27, pre-existing CVD, no diabetes at baseline +- Semaglutide 2.4mg weekly vs. placebo +- Primary outcome: MACE (cardiovascular death, non-fatal MI, non-fatal stroke) +- Approximately 33% of MACE reduction explained by early reductions in waist circumference +- Study led by John Deanfield (UCL) and colleagues +- Published in The Lancet, November 2025 +- ESC 2024 mediation analysis co-authored by Lincoff (Cleveland Clinic) -- 2.45.2